Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company

Dna, Genetic Material, Helix, Proteins, Biology

Image Source: Unsplash


Deals and Financings

  • Shanghai I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire an innovative China life science company.
  • RVAC Medicines, a Singapore mRNA platform company, completed a Series B funding led by CBC Group that brings total funds raised since inception to $140 million.
  • Vivo Capital will invest $60 million in a new JV formed with Arrowhead Pharma that will have China rights to four Arrowhead RNAi candidates.
  • Huadong Medicine of Hangzhou entered a $45 million deal for China rights to four novel hydroxyl dendrimer candidates developed by Ashvattha of Redwood City, CA.
  • Xbiome acquired global rights to a clinical-stage microbiome candidate for mild to moderate ulcerative colitis from Assembly Bio of South San Francisco.
  • Guizhou Sinorda Biomedicine, a novel cell and gene therapy company, announced a long-term strategic cell and gene therapy R&D partnership with CDMO Suzhou Porton.


Company News

  • Chimera Bio of South San Francisco won the $7.5 million Asian Fund for Cancer Research 2021 BRACE Award for its CAR-T research of China-important cancers.


Trials and Approvals

  • LianBio, a Shanghai-Princeton, reported its partner, Bristol-Myers Squibb, was approved for a US launch of Camzyos™ to treat obstructive hypertrophic cardiomyopathy.
  • Suzhou Transcenta dosed the first patient in a China Phase I trial of a novel humanized anti-sclerostin mAb therapy for osteoporosis.
  • Shenzhen SonoScape Medical released the latest software upgrade of its lead ultrasound product, S-Fetus 4.0, with new features based on deep learning.

Disclosure: None

How did you like this article? Let us know so we can better customize your reading experience.

Comments